Book Appointment
Book Appointment
Book Appointment

Blogs

  • Home
  • Dr. Avanish Saklani

CRS & HIPEC: Transforming Peritoneal Cancer Care

Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has revolutionized the treatment of cancers that spread to the peritoneum, the lining of the abdominal cavity. Previously considered difficult to treat, peritoneal metastases from colorectal, appendiceal, ovarian, and other cancers can now be managed with advanced surgical techniques that aim to remove visible tumors and target microscopic cancer cells.

This combined approach offers new hope to patients by providing a more aggressive yet targeted treatment strategy. By integrating surgery with heated chemotherapy delivered directly into the abdomen, CRS and HIPEC work together to improve survival outcomes while minimizing systemic side effects commonly associated with traditional chemotherapy.

What Is Cytoreductive Surgery (CRS)?

Cytoreductive Surgery focuses on removing all visible cancer deposits from the abdominal cavity. The goal is to reduce the tumor burden as much as possible before administering HIPEC therapy.

  • Removal of Visible Tumors – Surgeons carefully remove cancerous tissue from the peritoneal surfaces and affected organs.
  • Comprehensive Surgical Approach – Multiple procedures may be performed in a single operation to eliminate tumor deposits.
  • Improved Disease Control – Removing large tumor masses increases the effectiveness of subsequent chemotherapy.
  • Specialized Surgical Expertise – CRS requires advanced training and experience in complex abdominal cancer surgery.

Understanding HIPEC Therapy

After cytoreductive surgery is completed, HIPEC therapy is administered directly into the abdominal cavity. A heated chemotherapy solution is circulated within the abdomen for a specific duration to destroy any remaining microscopic cancer cells.

  • Heated Chemotherapy – The chemotherapy solution is warmed to enhance its cancer-killing effectiveness.
  • Direct Drug Delivery – Chemotherapy is delivered directly to the affected area, increasing local effectiveness.
  • Reduced Systemic Side Effects – Because the treatment is localized, patients often experience fewer side effects compared to intravenous chemotherapy.
  • Targeting Microscopic Disease – HIPEC helps eliminate cancer cells that may remain after tumor removal.

Benefits of CRS & HIPEC Treatment

The combination of CRS and HIPEC has become an important treatment option for selected patients with peritoneal surface malignancies.

  • Improved Survival Outcomes – Many patients experience significantly better long-term survival compared to traditional therapies.
  • Comprehensive Cancer Management – Treats both visible tumors and microscopic disease simultaneously.
  • Advanced Targeted Therapy – Direct chemotherapy delivery increases effectiveness against cancer cells.
  • Hope for Previously Untreatable Cases – Offers treatment possibilities for patients who previously had limited options.
  • Multidisciplinary Care – Requires coordination between surgical oncology, medical oncology, and specialized care teams.

Who Can Benefit from CRS & HIPEC?

CRS and HIPEC are most beneficial for carefully selected patients with cancers that have spread within the abdominal cavity but have not widely spread outside it. These may include colorectal cancer, appendiceal cancer, peritoneal mesothelioma, and certain ovarian cancers.

Evaluation by an experienced colorectal and peritoneal cancer specialist is essential to determine eligibility for this advanced treatment. With ongoing innovations in surgical oncology, CRS and HIPEC continue to transform the management of peritoneal cancers, offering patients better outcomes and renewed hope for long-term survival.